Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11441743 | 0.79 | GABRA1 (0.42) | GABRA1GABRB2ALDH1A1LMNA | |
| SCHEMBL11214636 | 0.79 | GABRA1 (0.56) | GABRA1GABRB2ALDH1A1LMNAPKM | |
| SCHEMBL23587494 | 0.77 | GABRA1 (0.38) | GABRA1GABRB2ALDH1A1LMNAGAA | |
| SCHEMBL13363795 | 0.77 | GABRA1 (0.38) | GABRA1GABRB2ALDH1A1LMNAGAA | |
| SCHEMBL21348074 | 0.72 | GABRA1 (0.35) | GABRA1GABRB2LMNAGAAMAPT | |
| SCHEMBL11139239 | 0.72 | GABRA1 (0.48) | GABRA1GABRB2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11441729 | 0.71 | GABRA1 (0.44) | GABRA1GABRB2ALDH1A1LMNAGAA | |
| SCHEMBL21999447 | 0.71 | GAA (0.34) | GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL21559977 | 0.68 | GABRA1 (0.43) | GABRA1GABRB2ALDH1A1LMNAMAPT | |
| SCHEMBL11428148 | 0.67 | GABRA1 (0.40) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10328078-B2 | Pteridine dione monocarboxylate transporter inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328078-B2 | Pteridine dione monocarboxylate transporter inhibitors | SLC16A1, SLC16A3, SLC16A7 | GABRA1 3305/4885GABRB2 2749/4885ALDH1A1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.